Your search for Warfarin returned 9 results

Findings may help with decision-making in this high-risk patient population.

Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.

The patients, a 71-year-old male and a 62 year-old-male, both on long-term warfarin therapy, presented to the emergency department with symptoms of COVID-19.

Apixaban is a direct oral anticoagulant that relies less on kidney excretion.

Investigators found an incremental increase in risks from oral anticoagulants as kidney function decreased, highlighting the need for more research to better understand bleeding risk and net benefit of treatment in the CKD population.

The patient developed a generalized maculopapular rash approximately 3 hours after receiving warfarin.

Moderate to severe hyperparathyroidism after kidney transplantation may have predisposed 2 cases to calciphylaxis, according to investigators.

Kidney injury may be less among patients with chronic kidney disease and atrial fibrillation taking apixaban versus warfarin for anticoagulation, new research suggests.

Antiplatelet therapy may delay progression of COPD, decrease the risk for acute exacerbations, improve quality of life, and even reduce all-cause mortality.